Physician profile

Adenike A Adeleke

Psychiatric/Mental Health (Nurse Practitioner) · Houston, TX

NPI 1235757014

$6,793.40

in general payments reported to CMS, 2019-2025

42 companies · $1,170 in 2025

The $1,170 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,312.29

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,172.53 2021-2025
Sunovion Pharmaceuticals INC. $1,085.90 2021-2022
Otsuka America Pharmaceutical, INC. $669.87 2021-2025 Rexulti, Abilify Maintena, Abilify Asimtufii
Teva Pharmaceuticals USA, INC. $464.58 2021-2022
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $436.25 2021-2025 Caplyta
Neos Therapeutics, Lp $264.44 2021-2023 Adzenys Xr-Odt
Alkermes, INC. $255.21 2021-2025 Aristada, Lybalvi
Corium, LLC $250.53 2021-2025 Azstarys
Neurocrine Biosciences, INC. $234.65 2021-2025
Beta Bionics, INC. $195.98 2023-2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset
Janssen Pharmaceuticals, INC $139.98 2022
Ironshore Pharmaceuticals INC. $136.14 2021
Lundbeck LLC $131.82 2021
Corcept Therapeutics $125.24 2023-2025 Korlym
Supernus Pharmaceuticals, INC. $104.56 2022
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Cequr Corporation $103.68 2025 Cequr Simplicity
Mannkind Corporation $96.83 2023-2025 Afrezza
Brainsway USA INC $96.12 2025 Deep Tms System
Adlon Therapeutics L.P. $89.70 2021
Madrigal Pharmaceuticals $68.02 2025 Rezdiffra
Vanda Pharmaceuticals INC. $66.64 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $56.44 2022
Sanofi-Aventis U.S. LLC $43.99 2023-2024
Averitas Pharma INC. $43.58 2024 Qutenza
Novo Nordisk INC $42.40 2023 Wegovy
Bausch Health US, LLC $42.24 2021-2022
Bayer Healthcare Pharmaceuticals INC. $35.00 2023-2024
Avanir Pharmaceuticals, INC. $31.08 2021
Almatica Pharma LLC $30.51 2022
Alexion Pharmaceuticals, INC. $30.33 2023 Strensiq
Ibsa Pharma INC. $30.00 2023-2024 Tirosint, Tirosint, Licart
Novartis Pharmaceuticals Corporation $25.25 2025
Radius Health, INC. $24.43 2023 Tymlos
Sun Pharmaceutical Industries INC. $22.33 2021
Kyowa Kirin, INC. $22.01 2024 Crysvita
Tris Pharma INC $20.96 2022
Alfasigma USA, INC. $18.59 2022
Xeris Pharmaceuticals, INC. $17.92 2024 Gvoke Hypopen
Validus Pharmaceuticals LLC $17.86 2022
Eisai INC. $17.40 2021
Alvogen INC $16.49 2025 Teriparatide
Tolmar, INC. $15.92 2025 Jatenzo

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adenike A Adeleke

$6,793.40

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $1,170 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).

https://glasscript.com/doctor/10967673/adenike-a-adeleke

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.